Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8179101 | 0.98 | HTT (0.59) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL407540 | 0.85 | ADRA2A (0.60) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL31407451 | 0.85 | ADRA2A (0.60) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL8186813 | 0.85 | ADRA2A (0.60) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL29841237 | 0.85 | ADRA2A (0.60) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL439092 | 0.85 | ADRA2A (0.60) | HTTCA2ADRA2AADRA1AHTR1A | |
| Bromide SCHEMBL11489853 | 0.83 | ADRA2A (0.58) | HTTCA2ADRA2AADRA1AHTR1A | |
| Hydrochloric Acid SCHEMBL783118 | 0.83 | ADRA2A (0.58) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL12309752 | 0.81 | POLB (0.62) | HTTCA2ADRA2AADRA1AHTR1A | |
| SCHEMBL8788249 | 0.81 | HTT (0.61) | HTTCA2ADRA2AADRA1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053260-B2 | Tri-cycle compound and applications thereof | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| EP-3587420-B1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| EP-1768970-B1 | SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-1968572-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2276481-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| EP-0252005-B1 | HYDROGENATED 1-BENZOOXACYCLOALKYL-PYRIDINE CARBOXYLIC-ACID COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-07-10 | — | — | EP | disclosed |
| EP-0429535-A1 | FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-05 | — | — | EP | disclosed |
| US-4957928-A | NOOTROPIC AGENTS, COGNITION ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
| EP-0359400-A1 | Fungicidal benzodioxane amine derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| CN-1040371-A | The preparation method of benzo two alkanamine derivatives | DU PONT (US) | 1990-03-14 | — | — | CN | disclosed |
| WO-1990002122-A1 | FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0252005-A1 | Hydrogenated 1-benzooxacycloalkyl-pyridine carboxylic-acid compounds | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
| EP-0003359-B1 | SPECIFIC OPTICAL ISOMERS OF 2-AMINOETHYL-1,4-BENZODIOXANES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | CIBA-GEIGY AG (CH) | 1981-02-11 | — | — | EP | disclosed |
| US-4187313-A | HYPOTENSIVE AGENTS, BRADYCARDIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-02-05 | — | — | US | disclosed |
| EP-0003359-A1 | Specific optical isomers of 2-aminoethyl-1,4-benzodioxanes, process for their preparation and their pharmaceutical compositions | CIBA-GEIGY AG (CH) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | SLC10A1, NR1H4, HAVCR2 | HTT 1159/4885CA2 2592/4885ADRA2A 4714/4885 |
| US-11053260-B2 | Tri-cycle compound and applications thereof | SLC10A1, NR1H4, HAVCR2 | HTT 1159/4885CA2 2592/4885ADRA2A 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.